Connect with us

Public Companies

3 Key Takeaways From the Negev Capital Roundtable at Psychedelic Capital

The post 3 Key Takeaways From the Negev Capital Roundtable at Psychedelic Capital appeared first on Microdose.

The rapidly emerging psychedelic space…

Published

on

The post 3 Key Takeaways From the Negev Capital Roundtable at Psychedelic Capital appeared first on Microdose.

The rapidly emerging psychedelic space is beginning to see its fair share of venture capitalists. Among them, Negev Capital stands out with a dynamic team of investors leading their pursuits in the psychedelic space. Their presentation at our June 2021 Psychedelic Capital event was both informative for investors and engaging for enthusiasts. Here are three key takeaways from the PsyCap roundtable discussion they hosted.

Get your FREE ticket for the upcoming Psychedelic Capital

Negev is Invested In the Right Companies Focusing On the Right Objectives

Key Takeaway #1: Negev Capital is Invested In the Right Companies Focusing On the Right Objectives

The VP of Drug Discovery at Bright Minds was one of the keynote members of Negev’s PsyCap roundtable discussion and represented a primary investment of the Negev Capital team. To quote the brilliant R&D professional, Carol Routledge, herself, Bright Mind is “totally focused on the mechanism and the reason why we’re focused on the mechanism is around treating patients and getting to as many patients as possible.”Indeed, with over thirty years of experience in UK and US biotech and pharma companies, she’s the right person for the job with the right objectives in mind. With goals like identifying exactly what is necessary for the antidepressant effect to take place when utilizing psychedelic medication and psychedelic-assisted psychotherapy, to narrower focuses like “receptor occupancy”, the Negev team is focusing on the right things. Big questions, such as whether one needs to even be conscious for the mystical experience (or whether the benefits of it can be achieved under anesthesia are still under investigation by the brilliant minds that Negev is invested in. Other experts featured were Gideon Shapiro, a skilled organic chemist that graduated from UNC and UC Berkeley, Ken Belotsky, partner at the Negev, and Dr. Stuart Seidman, Negev partner and active psychiatrist out of Manhattan. This expert panel brings to light important issues in the psychedelic space and, more importantly, solutions to the active psychedelic investment sphere.

Negev Capital’s Portfolio Spotlights Companies With Proprietary Molecules Around DMT

Key Takeaway #2: Negev Capital’s Portfolio Spotlights Companies With Proprietary Molecules Around DMT

Microdose has extensively covered the benefits of utilizing DMT over other psychedelic compounds due to the short-acting yet profoundly mystical nature of this particular tryptamine. Indeed, companies that Negev is invested in have proprietary molecules around DMT—an important IP play in the psychedelic field. Of these molecules, it’s notable that they each have different half-lives, offering unique advantages to each potential candidate. The variables become even more complex when considering the route of administration can be varied as well when administering DMT. Indeed, companies like Entheon Biomedical are developing therapies that involve intravenous DMT administration for opioid addiction. To harken back to our first takeaway, the teams, such as Bright Minds, that Negev is invested in, know what to focus on. For instance, providing a “pleasant experience” is not the top of the priority list for teams like Bright Minds, who are more focused on providing clinically significant healing rather than promising a “good trip”. By using a drug like DMT, which is clinically proven to be safe, helps teams like Bright Minds circumvent otherwise serious safety limitations posed by psychedelics such as ibogaine, for instance.
Small Pharma is Another Key Investment of the Negev Capital Team

Key Takeaway #3: Small Pharma is Another Key Investment of the Negev Capital Team

Small Pharma is a key investment of the Negev Capital team and their specific focus on DMT therapeutics and DMT-assisted psychotherapy for the treatment of depressive disorders is worth noting. In particular worth noting is their current phase 2A proof of concept clinical trial evaluating tolerability, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of DMT plus therapy in healthy festival-goers. This valuable data will help progress the field of DMT therapeutics overall and benefit key players that Negev is invested in.

A Look Ahead for Negev and its Holdings

The Negev roundtable discussion at our June 2021 Psychedelic Capital event spotlighted some seriously significant issues in the current psychedelic space—especially when it comes to psychedelics and venture capital. This PsyCap panel featured some bright minds (see what we did there?), from the company Bright Minds to the pioneers at Small Pharma and the leaders at Negev. Be sure to check them out and watch the recording if you missed this exciting roundtable discussion.

Read More

Trending